Key result
The ACE I/D polymorphism was not significantly associated with laryngeal cancer prevalence (p=0.079), but the DD genotype was associated with an 8.3-fold increased risk of lymph node metastasis.
Why the study?
The study aimed to compare the distribution of the ACE I/D polymorphism between patients with laryngeal cancer and controls, and examine its association with clinical parameters.
Is the ACE I/D polymorphism associated with the prevalence of laryngeal cancer or its clinical parameters?
Case-Control (n=105)
Is the ACE I/D polymorphism associated with the prevalence of laryngeal cancer or its clinical parameters?
p-value: p=0.079
The ACE DD genotype may increase the risk of lymph node metastasis in patients with laryngeal cancer, although it does not appear to affect overall disease prevalence.
Objectives: The aim of this study was to compare the distribution of the angiotensin-converting enzyme (ACE) I/D polymorphism between patients with laryngeal cancer (LC) and a control group and to examine the distribution of this polymorphism with clinical parameters related to LC. Methods: We enrolled 44 LC patients and 61 healthy controls. The ACE I/D polymorphism was genotyped with the PCR-RFLP method. The distribution of ACE genotypes (II, ID, and DD) and alleles (I or D) was evaluated with Pearson's chi-square test, and logistic regression analysis was performed for statistically significant parameters. Results: There was no significant difference in ACE genotypes and alleles between LC patients and controls (p = 0.079 and p = 0.068, respectively). Among clinical parameters related to LC (extension of tumour, node metastasis, tumour stage and tumour location), only the presence of node metastasis was found to be significant in terms of ACE DD genotype (p = 0.137, p = 0.031, p = 0.147, p = 0.321 respectively). In the logistic regression analysis, the ACE DD genotype was increased 8.3 fold in nodal metastases. Conclusions: The findings of the study suggest that ACE genotypes and alleles do not affect the prevalence of LC, but the DD genotype of ACE polymorphism may increase the risk of lymph node metastasis in LC patients.
No takes yet. Share an insight, caveat, or question.
Kumbul et al. (2023) conducted a case-control in Laryngeal cancer (n=105). Angiotensin-converting enzyme (ACE) I/D polymorphism vs. Healthy controls was evaluated on Distribution of ACE genotypes between laryngeal cancer patients and controls (p=0.079). The ACE I/D polymorphism was not significantly associated with laryngeal cancer prevalence (p=0.079), but the DD genotype was associated with an 8.3-fold increased risk of lymph node metastasis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: